YaSheng Group

Ascentage Pharma is a global biopharmaceutical company headquartered in Suzhou, China, dedicated to developing innovative therapies for cancers, hepatitis B virus (HBV), and age-related diseases. The company focuses on disrupting protein-protein interactions (PPIs) to restore apoptosis, with a robust pipeline targeting the BCL-2, IAP, and MDM2-p53 pathways. Its lead product, olverembatinib (HQP1351), is a third-generation BCR-ABL inhibitor approved in China for the treatment of drug-resistant chronic myeloid leukemia. Ascentage maintains a significant R&D presence in both China and the United States and has established strategic collaborations with global leaders like Takeda and Merck. The company is a pioneer in the field of apoptosis-targeting therapies and continues to expand its clinical programs globally.